Farxiga Gets FDA Greenlight for CKD

(MedPage Today) -- FDA expanded the indication for dapagliflozin (Farxiga) into chronic kidney disease (CKD).
The drug, which first entered the market for type 2 diabetes in 2014, was approved to reduce the risk of kidney function decline, kidney...